Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL. Hartwell MJ, et al. Among authors: pawarode a. JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. JCI Insight. 2017. PMID: 28194439 Free PMC article.
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S. Magenau J, et al. Among authors: pawarode a. Blood. 2011 Oct 13;118(15):4258-64. doi: 10.1182/blood-2011-06-358010. Epub 2011 Aug 12. Blood. 2011. PMID: 21841163 Free article. Clinical Trial.
TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.
Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE. Choi SW, et al. Among authors: pawarode a. Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30. Biol Blood Marrow Transplant. 2012. PMID: 22469883 Free PMC article. Clinical Trial.
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Choi SW, et al. Among authors: pawarode a. Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30. Lancet Oncol. 2014. PMID: 24295572 Free PMC article. Clinical Trial.
Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW. Gatza E, et al. Among authors: pawarode a. Biol Blood Marrow Transplant. 2014 Sep;20(9):1426-34. doi: 10.1016/j.bbmt.2014.05.023. Epub 2014 Jun 2. Biol Blood Marrow Transplant. 2014. PMID: 24892263 Free PMC article. Clinical Trial.
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC. Magenau JM, et al. Among authors: pawarode a. Ann Hematol. 2015 Jun;94(6):1033-41. doi: 10.1007/s00277-015-2349-4. Epub 2015 Mar 19. Ann Hematol. 2015. PMID: 25784222
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.
Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW. Song Y, et al. Among authors: pawarode a. Bone Marrow Transplant. 2016 Apr;51(4):511-520. doi: 10.1038/bmt.2015.170. Epub 2015 Jul 20. Bone Marrow Transplant. 2016. PMID: 26191952 Free PMC article. Clinical Trial.
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR. Pawarode A, et al. Biol Blood Marrow Transplant. 2016 Jan;22(1):54-60. doi: 10.1016/j.bbmt.2015.07.021. Epub 2015 Jul 26. Biol Blood Marrow Transplant. 2016. PMID: 26211984 Free article. Clinical Trial.
72 results